![Camilla Simpson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Camilla Simpson
Director/Board Member at
SPRUCE BIOSCIENCES, INC.
Net worth: - $ as of 2026-06-29
Profile
Camilla V.
Simpson is the founder of Rare Strategic LLC, founded in 2019, serving as President & Managing Member.
Current jobs include Chief Executive Officer at Zehna Therapeutics, Inc. since 2021, Independent Director at Spruce Biosciences, Inc. since 2017, Director at Dyve Biosciences, Inc. since 2020, and Independent Director at GRI Bio, Inc. since 2023.
Former jobs include Director at Aristea Therapeutics, Inc., Director at Vallon Pharmaceuticals, Inc., Senior VP & Head-Product Portfolio Development at BioMarin Pharmaceutical, Inc. from 2017 to 2019, and VP-Regulatory Affairs & Business Development at Shire Pharmaceuticals, Inc. Education includes graduate studies at the University of London, undergraduate studies at Kingston University, and undergraduate studies at National University of Ireland Galway.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-05-20 | 0 ( -.--% ) | - $ | 2026-06-29 | |
GRI BIO, INC. -.--% | 2026-01-16 | 0 ( -.--% ) | - $ | 2026-06-29 |
Camilla Simpson active positions
| Companies | Position | Start |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Director/Board Member | 2017-09-30 |
| GRI BIO, INC. | Director/Board Member | 2023-04-23 |
Rare Strategic LLC | Founder | 2019-03-31 |
Dyve Biosciences, Inc.
 Dyve Biosciences, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Director/Board Member | 2020-11-30 |
Zehna Therapeutics, Inc.
 Zehna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops non-bactericidal inhibitors for cardiovascular and chronic kidney diseases | Chief Executive Officer | 2021-03-31 |
Former positions of Camilla Simpson
| Companies | Position | End |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 2019-03-31 |
| GRI BIOPAR | Director/Board Member | - |
Aristea Therapeutics, Inc.
 Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies to treat serious inflammatory diseases | Director/Board Member | - |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | General Counsel | - |
Training of Camilla Simpson
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
68
1st degree connections
12
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 12 |
|---|---|
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
University of London
 University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kingston University
 Kingston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Spruce Biosciences, Inc.
 Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders | Health Technology |
National University of Ireland Galway
 National University of Ireland Galway Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aristea Therapeutics, Inc.
Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies to treat serious inflammatory diseases | Health Technology |
Dyve Biosciences, Inc.
Dyve Biosciences, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Health Technology |
Rare Strategic LLC | |
Vallon Pharmaceuticals, Inc.
 Vallon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and commercializes proprietary biopharmaceutical products | Health Technology |
Zehna Therapeutics, Inc.
Zehna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops non-bactericidal inhibitors for cardiovascular and chronic kidney diseases | Health Technology |
GRI Bio, Inc.
 GRI Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of inflammatory, fibrotic and autoimmune diseases | Health Technology |
- Stock Market
- Insiders
- Camilla Simpson
